Symptom checks and self-monitoring for MS patientsSanofi Genzyme eHealth App
Sanofi Genzyme is one of the world's leading biotechnology companies and focuses on rare diseases and multiple sclerosis (MS). One Shoe developed the LEMCHECK app for Genzyme that supports MS patients with symptom checks and self-monitoring.
eHealth application for people with MS
In addition to their current digital channels, Sanofi Genzyme wished to develop an eHealth app for people in Europe, the Middle East and Africa with MS who have been prescribed with the medications AUBAGIO® and LEMTRADA®. Sanofi Genzyme and One Shoe worked closely together to design and develop the native iOS and Android app LEMCHECK™ for patients with the medicine LEMTRADA®.
LEMCHECK app supports self-monitoring of MS patients
The medicine LEMTRADA® (alemtuzumab) is indicated for the treatment of patients with relapsing-remitting MS (RRMS). Patients treated with LEMTRADA® need monthly monitoring until 48 months after the last treatment. The LEMCHECK™ app, among other objectives, serves to support the adherence of these patients during the self-monitoring activities.
Support for self-monitoring activities
The LEMCHECK™ app helps patients to:
- comply with monthly tests
- plan self-check activities
- log findings
- share findings with their physician
- identify and report symptoms
- have better understanding over their treatment